Abstract:Abstract 4815 Introduction: Acute myeloid leukemia (AML) is the most common type of adult leukemia for which cytosine arabinoside(Ara-C)-based chemotherapy is the main treatment. However, there is a significant difference in treatment response and survival, especially among large groups of patients with the same disease classification. Single nucleotide polymorphisms within the nucleotide excision repair pathway may alter the susceptibility of leukemia cells to chemotherapy. We investigated the role of six single nucleotide polymorphisms (ERCC5rs76871136, ERCC5rs77569659, ERCC5rs873601, XPCrs2228000, XPCrs2228001, and XPCrs1870134) within the nucleotide excision repair pathway on the outcome of patients with AML treated with cytosine arabinoside-based chemotherapy. Methods: One hundred fifty-one patients with AML in a Chinese population were enrolled in this study. Patients diagnosed with other cancers or other hematological malignancies were excluded in this study. This study was approved by the ethics committee of Southeast University in compliance with Chinese guidelines for blood donation, and informed consent for genetic analysis was obtained from all participants according to the Declaration of Helsinki. All patients received Ara-C-based standard induction chemotherapy regimens. Patients were divided into three groups, according to cytogenetic risk. Moreover, the evaluation standard of these patients were evaluated by age(£40 years, 40–60 years, and 360 years), WBC (>50 ′ 109/L vs. £50 ′ 109/L), hemoglobin level (>100 g/L vs. £100 g/L), and platelet count (>60 ′ 109/L vs. £60 ′ 109/L). Genotypes were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Deviations from the Hardy–Weinberg equilibrium for genotypes and haplotype frequencies as well as haplotype–trait associations were assessed with Pearson's c2 analysis using SHEsis. Once the expected number in any cell was less than five, demographic and clinical data across genotypes were compared using Pearson's c2analysis or Fisher's exact test. Significant genotypic differences among the different responders were calculated using Pearson's c2analysis. P <0.05 was considered statistically significant. We estimated the relative risk of responding to treatment with the genotypes as odds ratio(OR) and 95% confidence intervals(95%CI) using conditional logistic regression with adjustment for the effects of covariates. All statistical tests were two-sided and performed using SPSS 17.0. Results: Genotype frequencies for the polymorphisms were found to be in Hardy–Weinberg equilibrium. The results indicated that the distribution of three genotypes of XPCrs1870134 significantly differed among the cytogenetic risk groups (P = 0.04). The frequency of the CC genotype of XPCrs2228001 was significantly higher in male patients than in female patients (P = 0.03), whereas that of the CC genotype of XPCrs2228000 was significantly higher in patients with a hemoglobin level of 100 g/L or less compared with those who had a hemoglobin level greater than 100 g/L (P = 0.039).Moreover, patients carrying at least one variant allele (XPCrs2228001AA+CC) were more likely to respond better than those who did not carry a variant. However, no significant association was detected between polymorphisms in ERCC5 and treatment response. Conclusions: These findings suggest that XPC polymorphisms are important markers for the outcome of patients with AML in the Chinese population. Disclosures: No relevant conflicts of interest to declare.

Genetic variants of nucleotide excision repair pathway and outcomes of induction therapy in acute myeloid leukemia

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

Genetic Variations Of Dna Repair Genes And Their Prognostic Significance In Patients With Acute Myeloid Leukemia

Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Polymorphisms in XPC Provide Prognostic Information in Acute Myeloid Leukemia

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Genetic Variants in Nucleotide Excision Repair Pathway Predict Survival of Esophageal Squamous Cell Cancer Patients Receiving Platinum‐based Chemotherapy

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

[Polymorphisms in Nucleotide Excision Repair Genes XPC and XPD and Clinical Responses to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer].

Relationship between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in advanced non-small cell lung cancer patients

Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.

XPA tumor variant leads to defects in NER that sensitize cells to cisplatin

XPA tumor variants lead to defects in NER that sensitize cells to cisplatin

Genetic Variants in ERCC1 and XPC Predict Survival Outcome of Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Therapy

[Polymorphisms of RAD51(G135C) and XRCC3(C241T) Genes and Correlations Thereof with Prognosis and Clinical Outcomes of Acute Myeloid Leukemia].

DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy.

Genetic Variation in DNA-repair Pathways and Response to Radiochemotherapy in Esophageal Adenocarcinoma: a Retrospective Cohort Study of the Eastern Cooperative Oncology Group